Pharmaceutical grade DOTATOC kits compliant with all the quality control criteria were formulated and radiolabeled with 68Ga in high yields. Comparison with module-based ⁶⁸Ga-DOTATOC established product equivalency. Clinical utility was evaluated in patients with histopathologically confirmed well-differentiated neuroendocrine tumors. Kit-based preparation of ⁶⁸Ga-DOTATOC could identify sites of primary and metastatic disease. PET/CT images of patients conformed to the established criteria for somatostatin imaging agents and clinical expectations. Results of this study emphasize the potential of kit-based ⁶⁸Ga-DOTATOC for PET imaging of neuroendocrine tumors.